Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460809 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL9015743 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL1775528 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL14064188 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL22983972 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL2460807 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL22984023 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL22983968 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL23517951 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 | |
| SCHEMBL6250998 | 1.00 | TYMS (0.56) | TYMSPOLBTYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020142414-A1 | Process for the preparation of protease inhibitors | UCP GEN-PHARMA AG (CH) | 2002-10-03 | — | — | US | disclosed |
| US-6410272-B1 | GENERATION OF HURIDIN COMPOUNDS; OBTAIN YEAST CELLS, TRANSFORM WITH VECTORS CODING HURIDIN COMPOUNDS, ISOLATE HURIDIN COMPOUND | CIBA-GEIGY CORPORATION A CORP. OF NEW YORK | 2002-06-25 | — | — | US | disclosed |
| US-6342373-B1 | ACETYL DERIVATIVES OF AMINO ACID SEQUENCES, CULTURES OF ESCHERICHIA OR SACCHAROMYCES AND EXPRESSION VECTORS | UCP GEN-PHARMA AG (CH) | 2002-01-29 | — | — | US | disclosed |
| US-5728549-A | GENE EXPRESSION VECTORS WITH CONTROLLING SEQUENCES OF DNA | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| US-5519126-A | COMBATTING DISEASES BY BIOCHEMICL INTERVENTION AT THE RNA AND DNA LEVEL | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1996-05-21 | — | — | US | disclosed |
| US-5422249-A | Polypeptides | CIBA-GEIGY CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0558749-A1 | ANTISENSE NUCLEIC ACID DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1993-09-08 | — | — | EP | disclosed |
| EP-0406309-A4 | OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES | — | 1992-08-19 | — | — | EP | disclosed |
| EP-0225633-B1 | PRODUCTION OF THROMBIN INHIBITORS | CIBA-GEIGY AG (CH) | 1992-08-12 | — | — | EP | disclosed |
| EP-0406309-A1 | OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES | THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1991-01-09 | — | — | EP | disclosed |
| WO-1989009221-A1 | OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1989-10-05 | — | — | WO | disclosed |
| US-4720483-A | Oligopeptides and intermediates and processes for their manufacture | CIBA-GEIGY CORPORATION (US) | 1988-01-19 | — | — | US | disclosed |
| EP-0225633-A2 | Production of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1987-06-16 | — | — | EP | disclosed |
| US-4469863-A | ANTITUMOR AGENTS, VIRICIDES | GENTA INCORPORATED | 1984-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142414-A1 | Process for the preparation of protease inhibitors | EGLN2, EGLN1, PREP | TYMS 3023/4885POLB 549/4885TYMP 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.